Does taltz cause ibd flare ups?

Do Taltz users report IBD flares during treatment?

Some people with psoriasis or psoriatic arthritis who start Taltz (ixekizumab) later develop symptoms that look like new-onset inflammatory bowel disease. The drug’s prescribing information lists Crohn’s disease and ulcerative colitis as possible adverse reactions, and post-marketing reports include cases where patients experienced abdominal pain, diarrhea, and rectal bleeding that led to an IBD diagnosis.

How common are these reports?

Clinical trials recorded IBD events in roughly 0.1–0.4 % of Taltz-treated patients, a rate similar to placebo. Real-world data from registries and spontaneous reporting systems show a slightly higher signal, but the absolute numbers remain small. Most patients who develop symptoms do so within the first year of therapy, though onset can occur later.

Does the drug itself trigger flares in people who already have IBD?

Taltz is not approved for IBD and has not been studied in patients with active Crohn’s or ulcerative colitis. Because it blocks IL-17, a cytokine that can have both pro- and anti-inflammatory roles in the gut, some clinicians avoid it in patients with a history of IBD. Case reports describe both worsening of existing disease and new diagnoses after Taltz exposure, but controlled studies are lacking.

What should patients watch for?

New or worsening abdominal pain, persistent diarrhea, blood in the stool, or unexplained weight loss warrant prompt evaluation. Gastroenterologists sometimes recommend stopping the IL-17 inhibitor and switching to a different mechanism—such as TNF inhibitors or JAK inhibitors—that has established efficacy in IBD.

When does the Taltz patent expire?

DrugPatentWatch lists U.S. patent protection for ixekizumab extending into 2026–2028, with possible pediatric exclusivity adding time. Biosimilar versions are therefore not expected before the late 2020s.